Alkylating agents: all 3,295 studies that test it
Page 3 of 33. Open to participants first (456), then studies with results posted, then the rest; newest registration first within each.
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)RecruitingNCT06401330Phase 3
- The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential TherapyRecruitingNCT06388720Phase 2
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingNCT06383572Phase 1/2
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
- Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory NeuronopathyRecruitingNCT06373211Phase 2
- TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.RecruitingNCT06353360Phase 2
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
- Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for TransplantationRecruitingNCT06324266Phase 2/3
- Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesRecruitingNCT06316076Phase 1
- Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).RecruitingNCT06297512Phase 2
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingNCT06291064Phase 2
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
- Niraparib and Temozolomide in Patients GlioblastomaNot yet recruitingNCT06258018Phase 1/2
- Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)RecruitingNCT06255210Phase 2
- Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDSRecruitingNCT06247917Phase 2
- the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous NephropathyRecruitingNCT06245707Not applicable
- Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 BlockadeNot yet recruitingNCT06238245Phase 2
- Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic CancerNot yet recruitingNCT06233877Phase 2
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingNCT06227065Phase 2
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingNCT06202066Phase 2
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 2
- Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage SyndromeRecruitingNCT06198842Phase 2
- Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCRecruitingNCT06193486Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated GlioblastomaNot yet recruitingNCT06186440Phase 1/2
- POST URS Chemotherapy InstillationRecruitingNCT06167057Not applicable
- Study of Olutasidenib and Temozolomide in HGGRecruitingNCT06161974Phase 2
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
- Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in ChildrenRecruitingNCT06099366Phase 2
- BRE-08 Phase II Study of CMC Regimen for Early Stage Breast CancerRecruitingNCT06085742Phase 2
- A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
- The Optimization of Conditioning Regimen for HLA Matched HSCT in SAARecruitingNCT06069180Phase 4
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)RecruitingNCT06066424Phase 1
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingNCT06058377Phase 3
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingNCT06047977Phase 1
- Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialRecruitingNCT06042569Phase 2
- An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine TumorsRecruitingNCT06038461Phase 1/2
- Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06028828Phase 2
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid TumorsRecruitingNCT06013111Phase 1
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
- Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial CarcinomaNot yet recruitingNCT05979909Phase 1
- Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With YescartaRecruitingNCT05950802Phase 1
- A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLHRecruitingNCT05936086Not applicable
- The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.RecruitingNCT05931328Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingNCT05909059Phase 2
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingNCT05903937Phase 1
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
- Melphalan Chemoreduction for Ocular MelanomaEnrolling by invitationNCT05893654Phase 1/2
- A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGLRecruitingNCT05885386Phase 2
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
- Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System InvolvementRecruitingNCT05854225Not applicable
- Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical TransplantRecruitingNCT05849207Phase 1
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Phase 2
- Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal SarcomaEnrolling by invitationNCT05844813Phase 4
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingNCT05843253Phase 2
- Adaptive Radiation in Anal CancerRecruitingNCT05838391Not applicable
- Modified BEAM Regimen for T Cell Lymphoma Underwent ASCTNot yet recruitingNCT05814718Not applicable
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruitingNCT05765812Phase 1/2
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic AnemiaRecruitingNCT05757310Phase 1
- Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic TumorsRecruitingNCT05755854Phase 1
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid MalignanciesRecruitingNCT05705570Phase 1
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLRecruitingNCT05702853Phase 1/2
- Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid TumorsRecruitingNCT05693844Phase 1/2
- HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid TumorsRecruitingNCT05681650Phase 1/2
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingNCT05681260Phase 3
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationNCT05674539Phase 3
- Phase II Trial of Lung ChemoemobolizationRecruitingNCT05672108Phase 2
- The Efficacy and Safety of Temozolomide in SDH-deficient GISTRecruitingNCT05661643Phase 2
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
- EBV CAR-T Cells for Nasopharyngeal CarcinomaRecruitingNCT05654077Early Phase 1
- TIL Cells for the Treatment of the Advanced Solid Tumors PatientsNot yet recruitingNCT05649618Early Phase 1
- TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsNot yet recruitingNCT05648994Early Phase 1
- Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma PatientsRecruitingNCT05636787Phase 2
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
- CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNCT05617625Not applicable
- A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM MultiformeRecruitingNCT05600491Phase 3
- Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
- Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the BrainRecruitingNCT05588453Phase 1/2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingNCT05565105Phase 2
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2